Liquid biopsy in lung cancer: biomarkers for the management of recurrence and metastasis
Liquid biopsies have emerged as a promising tool for the detection of metastases as well as
local and regional recurrence in lung cancer. Liquid biopsy tests involve analyzing a …
local and regional recurrence in lung cancer. Liquid biopsy tests involve analyzing a …
Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA
V Yaghoubi Naei, P Bordhan… - Therapeutic …, 2023 - journals.sagepub.com
Over the past decade, the detection and analysis of liquid biopsy biomarkers such as
circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have advanced …
circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have advanced …
Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
Abstract People with Li–Fraumeni syndrome (LFS) harbor a germline pathogenic variant in
the TP53 tumor suppressor gene, face a near 100% lifetime risk of cancer, and routinely …
the TP53 tumor suppressor gene, face a near 100% lifetime risk of cancer, and routinely …
Sequence-based platforms for discovering biomarkers in liquid biopsy of non-small-cell lung cancer
Simple Summary A lack of sensitive biomarkers hinders lung cancer detection and
monitoring, resulting in late diagnosis and missed treatment response. Liquid biopsies have …
monitoring, resulting in late diagnosis and missed treatment response. Liquid biopsies have …
Cell-free DNA fragmentation patterns in a cancer cell line
Unique bits of genetic, biological and pathological information occur in differently sized cell-
free DNA (cfDNA) populations. This is a significant discovery, but much of the phenomenon …
free DNA (cfDNA) populations. This is a significant discovery, but much of the phenomenon …
Clinical application of molecular residual disease detection by circulation tumor DNA in solid cancers and a comparison of technologies
Q Dong, C Chen, Y Hu, W Zhang, X Yang… - Cancer Biology & …, 2023 - Taylor & Francis
Molecular residual disease (MRD), detected by circulating tumor DNA (ctDNA) can be
involved in the entire process of solid tumor management, including recurrence prediction …
involved in the entire process of solid tumor management, including recurrence prediction …
Integration of Cell-Free DNA End Motifs and Fragment Lengths Can Identify Active Genes in Liquid Biopsies
CT Maansson, LS Thomsen, P Meldgaard… - International Journal of …, 2024 - mdpi.com
Multiple studies have shown that cell-free DNA (cfDNA) from cancer patients differ in both
fragment length and fragment end motif (FEM) from healthy individuals, yet there is a lack of …
fragment length and fragment end motif (FEM) from healthy individuals, yet there is a lack of …
Use of ctDNA in early breast cancer: analytical validity and clinical potential
F Panet, A Papakonstantinou, M Borrell, J Vivancos… - npj Breast …, 2024 - nature.com
Circulating free tumor DNA (ctDNA) analysis is gaining popularity in precision oncology,
particularly in metastatic breast cancer, as it provides non-invasive, real-time tumor …
particularly in metastatic breast cancer, as it provides non-invasive, real-time tumor …
Circulating tumor DNA-minimal residual disease: an up-and-coming nova in resectable non-small-cell lung cancer
FQ Li, JW Cui - Critical Reviews in Oncology/Hematology, 2022 - Elsevier
Circulating tumor DNA (ctDNA) in the bloodstream can be used to reliably identify a minimal
residual disease (MRD). ctDNA-MRD has demonstrated clinical values as a predictive and …
residual disease (MRD). ctDNA-MRD has demonstrated clinical values as a predictive and …
Early changes in tumor-naive cell-free methylomes and fragmentomes predict outcomes in pembrolizumab-treated solid tumors
Early kinetics of circulating tumor DNA (ctDNA) in plasma predict response to
pembrolizumab but typically requires sequencing of matched tumor tissue or fixed gene …
pembrolizumab but typically requires sequencing of matched tumor tissue or fixed gene …